口服阿提诺洛尔与口服普罗普兰诺洛尔相比,用于婴儿血管瘤
Victor Meza Viteri1, Ligia Aranibar2,3
1Departamento de Dermatología, Facultad de Medicina, Universidad de los Andes, Santiago, Chile.
Medwave
|December 7, 2023
概括
口服阿提诺洛和普拉诺洛在治疗婴儿血管瘤方面表现出类似的有效性和安全性. 这次元分析发现,两种β-阻断剂之间完全缓解,复发率或不良事件的差异很小.
科学领域:
- 儿科皮肤病学 儿科皮肤病学
- 血管生物学 血管生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 婴儿血瘤是一种常见的儿童血管瘤.
- 口服普罗普拉诺洛尔是标准治疗方法,但有副作用.
- 口服阿提诺洛尔是潜在的替代品,因为它具有选择性作用.
研究的目的:
- 为了比较口服阿提诺洛尔与普拉诺洛尔在婴儿血管瘤的疗效和安全性.
- 评估治疗结果,包括缓解,复发和不良事件.
主要方法:
- 系统搜索Epistemonikos数据库的系统审查.
- 包括10项初级研究和3项随机试验.
- 证据确定性的元分析和GRADE评估.
主要成果:
- 在阿提诺洛和普拉诺洛之间完全缓解率几乎没有差异.
- 在血瘤活动评分下降和治疗后复发的类似结果.
- 两种治疗方法的不良和严重不良事件的风险相比较.
结论:
- 口服阿提诺洛尔和普拉诺洛尔在婴儿血管瘤的疗效和安全性相似.
- 有证据表明,治疗结果和副作用的差异很小.
- 可能需要进一步的研究以更高的确定性来证实这些发现.
相关概念视频
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
828
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
828
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
459
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
459
01:28Antihypertensive Drugs: Types of β-Blockers
691
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
691
01:16Antianginal Drugs: Nitrates and β-Blockers
596
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
596
01:18Drug Delivery: Enteral Route
460
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
460
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
624
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
624